# EDGAR Filing Document

**Accession Number:** 0001868726
**File Stem:** 0001868726-26-000036
**Filing Date:** 2026-5
**Character Count:** 147384
**Document Hash:** 1747ecf3f3d45470e588ef43083750dc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001868726-26-000036.hdr.sgml**: 20260511

**ACCESSION NUMBER**: 0001868726-26-000036

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 68

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260511

**DATE AS OF CHANGE**: 20260511

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OLAPLEX HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001868726
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40860
- **FILM NUMBER:** 26960787

**BUSINESS ADDRESS:**
- **STREET 1:** 432 PARK AVENUE SOUTH
- **STREET 2:** THIRD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10016
- **BUSINESS PHONE:** 310-691-0776

**MAIL ADDRESS:**
- **STREET 1:** 432 PARK AVENUE SOUTH
- **STREET 2:** THIRD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10016

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OLAPEX HOLDINGS, INC.
- **DATE OF NAME CHANGE:** 20210622

?xml version='1.0' encoding='ASCII'? olpx-20260331

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

________________________

**FORM 10-Q**

________________________

**(Mark One)**

**☒&nbsp;&nbsp;&nbsp;&nbsp;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the quarterly period ended March 31, 2026**

**or** 

☐&nbsp;&nbsp;&nbsp;&nbsp;**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the transition period from __________ to __________**

**Commission File Number** 001-40860

________________________

**Olaplex Holdings, Inc.**

**(Exact name of registrant as specified in its charter)** 

________________________

---

| | |
|:---|:---|
| Delaware | 87-1242679 |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

432 Park Avenue South, Third Floor, New York, NY 10016

**(Address of principal executive offices and zip code)**

(310) 691-0776

**(Registrant's telephone number, including area code)** 

________________________

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common stock, par value $0.001 per share | OLPX | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated Filer | ☐ | Accelerated Filer | ☒ |
| Non-accelerated Filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ☒

As of May 4, 2026, registrant had 672,042,176 shares of common stock, par value $0.001 per share, outstanding.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

**OLAPLEX HOLDINGS, INC.**

**TABLE OF CONTENTS** 

---

| | | |
|:---|:---|:---|
| | | **Page** |
| **[Part I.](#i5e139d266af54af18d6e7944fbeebefa_19)** | <u>[FINANCIAL INFORMATION](#i5e139d266af54af18d6e7944fbeebefa_19)</u> | |
| Item 1. | <u>[Condensed Consolidated Financial Statements (unaudited)](#i5e139d266af54af18d6e7944fbeebefa_22)</u> | [5](#i5e139d266af54af18d6e7944fbeebefa_22) |
| | <u>[Condensed Consolidated Balance Sheets](#i5e139d266af54af18d6e7944fbeebefa_25)</u> | [5](#i5e139d266af54af18d6e7944fbeebefa_25) |
| | <u>[Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income](#i5e139d266af54af18d6e7944fbeebefa_28)</u> | [6](#i5e139d266af54af18d6e7944fbeebefa_28) |
| | <u>[Condensed Consolidated Statements of Changes in Stockholders' Equity](#i5e139d266af54af18d6e7944fbeebefa_31)</u>&nbsp;&nbsp;&nbsp;&nbsp; | [7](#i5e139d266af54af18d6e7944fbeebefa_31) |
| | <u>[Condensed Consolidated Statements of Cash Flows](#i5e139d266af54af18d6e7944fbeebefa_37)</u> | [8](#i5e139d266af54af18d6e7944fbeebefa_37) |
| | <u>[Notes to Condensed Consolidated Financial Statements](#i5e139d266af54af18d6e7944fbeebefa_40)</u> | [9](#i5e139d266af54af18d6e7944fbeebefa_40) |
| [Item 2.](#i5e139d266af54af18d6e7944fbeebefa_112) | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i5e139d266af54af18d6e7944fbeebefa_112)</u>&nbsp;&nbsp;&nbsp;&nbsp; | [21](#i5e139d266af54af18d6e7944fbeebefa_112) |
| [Item 3.](#i5e139d266af54af18d6e7944fbeebefa_181) | <u>[Quantitative and Qualitative Disclosures about Market Risk](#i5e139d266af54af18d6e7944fbeebefa_163)</u>&nbsp;&nbsp;&nbsp;&nbsp; | [29](#i5e139d266af54af18d6e7944fbeebefa_163) |
| [Item 4.](#i5e139d266af54af18d6e7944fbeebefa_166) | <u>[Controls and Procedures](#i5e139d266af54af18d6e7944fbeebefa_166)</u>&nbsp;&nbsp;&nbsp;&nbsp; | [29](#i5e139d266af54af18d6e7944fbeebefa_166) |
| **[Part II.](#i5e139d266af54af18d6e7944fbeebefa_169)** | <u>[OTHER INFORMATION](#i5e139d266af54af18d6e7944fbeebefa_169)</u> | |
| [Item 1.](#i5e139d266af54af18d6e7944fbeebefa_172) | <u>[Legal Proceedings](#i5e139d266af54af18d6e7944fbeebefa_172)</u>&nbsp;&nbsp;&nbsp;&nbsp; | [30](#i5e139d266af54af18d6e7944fbeebefa_172) |
| Item 1A. | <u>[Risk Factors](#i5e139d266af54af18d6e7944fbeebefa_175)</u>&nbsp;&nbsp;&nbsp;&nbsp; | [30](#i5e139d266af54af18d6e7944fbeebefa_175) |
| [Item 2.](#i5e139d266af54af18d6e7944fbeebefa_178) | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#i5e139d266af54af18d6e7944fbeebefa_178)</u>&nbsp;&nbsp;&nbsp;&nbsp; | [32](#i5e139d266af54af18d6e7944fbeebefa_178) |
| Item 3. | <u>[Defaults Upon Senior Securities](#i5e139d266af54af18d6e7944fbeebefa_181)</u>&nbsp;&nbsp;&nbsp;&nbsp; | [32](#i5e139d266af54af18d6e7944fbeebefa_181) |
| Item 4. | <u>[Mine Safety Disclosures](#i5e139d266af54af18d6e7944fbeebefa_184)</u>&nbsp;&nbsp;&nbsp;&nbsp; | [32](#i5e139d266af54af18d6e7944fbeebefa_184) |
| [Item 5.](#i5e139d266af54af18d6e7944fbeebefa_187) | <u>[Other Information](#i5e139d266af54af18d6e7944fbeebefa_187)</u>&nbsp;&nbsp;&nbsp;&nbsp; | [32](#i5e139d266af54af18d6e7944fbeebefa_187) |
| [Item 6.](#i5e139d266af54af18d6e7944fbeebefa_190) | <u>[Exhibits](#i5e139d266af54af18d6e7944fbeebefa_190)</u>&nbsp;&nbsp;&nbsp;&nbsp; | [33](#i5e139d266af54af18d6e7944fbeebefa_190) |
| <u>[Signatures](#i5e139d266af54af18d6e7944fbeebefa_193)</u>&nbsp;&nbsp;&nbsp;&nbsp; | <u>[Signatures](#i5e139d266af54af18d6e7944fbeebefa_193)</u>&nbsp;&nbsp;&nbsp;&nbsp; | [34](#i5e139d266af54af18d6e7944fbeebefa_193) |

---

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

**GLOSSARY**

As used in this Quarterly Report on Form 10-Q ("Quarterly Report"), the terms identified below have the meanings specified below unless otherwise noted or the context indicates otherwise. Except where the context otherwise requires or where otherwise indicated, the terms "OLAPLEX" "we," "us," "our," "the Company," and "our business" refer to Olaplex Holdings, Inc. and its consolidated subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "<u>2022 Credit Agreement</u>" refers to the Credit Agreement, dated as of February 23, 2022, by and among Olaplex, Inc., Penelope Intermediate Corp., Goldman Sachs Bank USA, as administrative agent, collateral agent and swingline lender, and each lender and issuing bank from time to time party thereto. The 2022 Credit Agreement includes, among other things, a $675 million seven-year senior-secured term loan facility (the "2022 Term Loan Facility") and a $150 million five-year senior-secured revolving credit facility (the "2022 Revolver").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "<u>IPO</u>" refers to the initial public offering of shares of common stock of Olaplex Holdings, Inc., completed on October 4, 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "<u>Merger</u>" means the proposed merger of Merger Sub with and into Olaplex Holdings pursuant to the terms and conditions of the Merger Agreement, with Olaplex Holdings continuing as the surviving corporation and as a wholly owned subsidiary of Parent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "<u>Merger Agreement</u>" refers to the Agreement and Plan of Merger (as it may be amended, modified or supplemented from time to time) entered into on March 26, 2026, by and among Olaplex Holdings, Inc. ("Olaplex Holdings"), Henkel US Operations Corporation, a Delaware corporation ("Parent"), and Margot Acquisition Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "<u>Penelope</u>" refers to Penelope Holdings Corp., which is an indirect parent of Olaplex, Inc., the Company's primary operating subsidiary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "<u>Penelope Group Holdings</u>" refers to Penelope Group Holdings L.P., which prior to the IPO was the direct parent of Penelope.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "<u>Pre-IPO Stockholders</u>" refers to, collectively, (i) the former limited partners of Penelope Group Holdings prior to the Reorganization Transactions and (ii) holders of options to purchase shares of common stock of Penelope that were vested as of the consummation of the Reorganization Transactions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "<u>Pre-IPO Tax Assets</u>" refers to, collectively, certain tax attributes existing prior to the IPO, including tax basis in intangible assets and capitalized transaction costs relating to taxable years ending on or before the date of the IPO (calculated by assuming the taxable year of the relevant entity closes on the date of the IPO), that are amortizable over a fixed period of time (including in tax periods beginning after the IPO) and which are available to us and our wholly-owned subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "<u>Reorganization Transactions</u>" refers to the internal reorganization completed in connection with our IPO, pursuant to which Olaplex Holdings, Inc. became an indirect parent of Olaplex, Inc. For further information, see "Reorganization Transactions" in "Note 1 – Nature of Operations and Basis of Presentation" to our Consolidated Financial Statements included in Part II, Item 8 of our Annual Report on Form 10-K for the year ended December 31, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "<u>Tax Receivable Agreement</u>" refers to the income tax receivable agreement entered into by the Company in connection with the Reorganization Transactions under which the Company is required to pay the Pre-IPO Stockholders 85% of the cash savings, if any, in United States ("U.S.") federal, state or local tax that the Company actually realizes on its taxable income following the IPO, as specified in the Tax Receivable Agreement.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

**SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This Quarterly Report contains certain forward-looking statements and information relating to us that are based on the beliefs of our management as well as assumptions made by, and information currently available to, us. These statements include, but are not limited to, statements about our strategies, plans, objectives, expectations, intentions, expenditures and assumptions and other statements contained in or incorporated by reference in this Quarterly Report that are not historical or current facts. When used in this document, words such as "may," "will," "could," "should," "intend," "potential," "continue," "anticipate," "believe," "estimate," "expect," "plan," "target," "predict," "project," "forecast," "seek" and similar expressions as they relate to us are intended to identify forward-looking statements.

The forward-looking statements in this Quarterly Report reflect our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operation. Examples of forward-looking statements include, among others, statements we make regarding: our proposed Merger; the expected timing of the completion of the Merger; the ability to complete the Merger considering the various closing conditions; our financial position, liquidity, capital structure, sales and operating results; our business plans, strategies, investments and objectives; demand for our products; general economic and industry trends, including tariffs; our business prospects; our marketing and brand strategies; innovation and new product introduction; our international operations; changes in laws and regulations; future payments under our Tax Receivable Agreement; our supply chain and global distribution network; and interest rate derivatives. Forward-looking statements are predictions based upon assumptions that may not prove to be accurate, and they are not guarantees of future performance. As such, you should not place significant reliance on our forward-looking statements. Neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements, including any such statements taken from third party industry and market reports.

Forward-looking statements involve known and unknown risks, inherent uncertainties and other factors that are difficult to predict which may cause our actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements, including, without limitation, the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• uncertainties as to the timing or completion of the Merger, including the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement and circumstances requiring us to pay a termination fee or damages under the Merger Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the effects of the proposed Merger (or the announcement or pendency thereof) on relationships with associates, customers, manufacturers, suppliers, employees (including the risks relating to the ability to retain or hire key personnel), other business partners or governmental entities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the risk that the proposed Merger will divert management's attention from our ongoing business operations or otherwise disrupt our ongoing business operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks associated with litigation relating to the proposed Merger;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our dependence on the success of our business transformation plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• competition in the beauty industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to effectively maintain and promote a positive brand image, expand our brand awareness and maintain consumer confidence in the quality, safety and efficacy of our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to anticipate and respond to market trends and changes in consumer preferences and execute on our growth strategies and expansion opportunities, including with respect to new product introductions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to develop, manufacture and effectively and profitably market and sell future products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to attract new customers and consumers and encourage consumer spending across our product portfolio;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to successfully implement new or additional marketing efforts;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our relationships with and the capabilities and performance of our suppliers, manufacturers, distributors and retailers and our ability to manage our supply chain, including sourcing, manufacturing and quality control;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our dependence on a limited number of customers for a large portion of our net sales;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to limit the illegal distribution and sale by third parties of counterfeit versions of our products or the unauthorized diversion by third parties of our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to accurately forecast customer and consumer demand for our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• impacts on our business from political, regulatory, economic, trade and other risks associated with operating internationally;

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to attract and retain senior management and other qualified personnel;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on our and our third-party service providers' information technology;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to maintain the security of confidential information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to establish and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the outcome of litigation and regulatory proceedings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of changes in federal, state and international laws, regulations and administrative policy, tariffs and other trade policies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under the 2022 Credit Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to service our existing indebtedness and obtain additional capital to finance operations and our growth opportunities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• volatility of our stock price;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our "controlled company" status and the influence of investment funds affiliated with Advent International, L.P. over us;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of general economic conditions, disruptions in business conditions, and the financial strength of our consumers and customers on our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• fluctuations in our quarterly results of operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in our tax rates and our exposure to tax liability;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to integrate or realize the intended benefits of our acquisitions or strategic investments; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the other factors identified in the "Risk Factors" section of this Quarterly Report, the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2025, as amended (the "2025 Form 10-K") and in other documents that we file with the U.S. Securities and Exchange Commission from time to time.

Many of these factors are macroeconomic in nature and are, therefore, beyond our control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from those described in this Quarterly Report as anticipated, believed, estimated, expected, intended, planned or projected. We discuss many of these risks in greater detail in the "Risk Factors" section of this Quarterly Report and in the "Risk Factors" section of our 2025 Form 10-K. The forward-looking statements included in this Quarterly Report are made only as of the date hereof. Unless required by law, we neither intend nor assume any obligation to update these forward-looking statements for any reason after the date of this Quarterly Report to conform these statements to actual results or to changes in our expectations or otherwise.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

PART I - FINANCIAL INFORMATION

**ITEM 1. Condensed Consolidated Financial Statements (unaudited)**

**OLAPLEX HOLDINGS, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS** 

*(amounts in thousands, except per share and share data)* 

*(Unaudited)* 

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| **Assets** | | |
| Current Assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $326169 | $318731 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowances of $14,503 and $18,123 | 37501 | 29013 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory | 66364 | 60215 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 16227 | 62387 |
| Total current assets | 446261 | 470346 |
| Property and equipment, net | 1516 | 1422 |
| Intangible assets, net | 834864 | 847821 |
| Goodwill | 168300 | 168300 |
| Deferred tax assets |  | 46 |
| Other assets | 9253 | 9552 |
| Total assets | $1460194 | $1497487 |
| **Liabilities and stockholders' equity** |  |  |
| Current Liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $29184 | $8117 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 32758 | 85304 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of Related Party payable pursuant to Tax Receivable Agreement | 9206 | 9206 |
| Total current liabilities | 71148 | 102627 |
| Long-term debt | 352484 | 352290 |
| Deferred tax liabilities | 929 | 5283 |
| Related Party payable pursuant to Tax Receivable Agreement | 155858 | 155858 |
| Other liabilities | 1789 | 2039 |
| Total liabilities | 582208 | 618097 |
| Commitments and contingencies (Note 12) |  |  |
| Stockholders' equity (Notes 1 and 10): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.001 par value per share; 2,000,000,000 shares authorized, 671,711,593 and 669,076,651 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 672 | 669 |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 346086 | 342345 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (198) | (337) |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 531426 | 536713 |
| Total stockholders' equity | 877986 | 879390 |
| Total liabilities and stockholders' equity | $1460194 | $1497487 |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

**OLAPLEX HOLDINGS, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME** 

*(amounts in thousands, except per share and share data)* 

*(Unaudited)*

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Net sales | $99369 | $96978 |
| Cost of sales: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of product (excluding amortization) | 25293 | 27230 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of patented formulations | 2416 | 2392 |
| Total cost of sales | 27709 | 29622 |
| Gross profit | 71660 | 67356 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general, and administrative | 65951 | 47987 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of other intangible assets | 10820 | 10893 |
| Total operating expenses | 76771 | 58880 |
| Operating (loss) income | (5111) | 8476 |
| Interest expense | 7132 | 13725 |
| Interest income | (2702) | (5952) |
| Other expense (income), net | 142 | (178) |
| (Loss) Income before provision for income taxes | (9683) | 881 |
| Income tax (benefit) provision | (4396) | 416 |
| Net (loss) income | $(5287) | $465 |
| Net (loss) income per share: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $(0.01) | $0.00 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(0.01) | $0.00 |
| Weighted average common shares outstanding: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 669942446 | 664685462 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 669942446 | 666460714 |
| Other comprehensive income: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain on derivatives, net of income tax effect | $139 | $17 |
| Total other comprehensive income | 139 | 17 |
| Comprehensive (loss) income | $(5148) | $482 |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

**OLAPLEX HOLDINGS, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY** 

*(amounts in thousands, except number of shares)* 

*(Unaudited)* 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | | | | |
| | **Shares** | **Amount** |<br>**Additional Paid<br> in Capital** |<br>**Accumulated Other Comprehensive Loss** |<br>**Retained <br>Earnings** |<br>**Total Stockholders' Equity** |
| **Balance - December 31, 2025** | 669076651 | $669 | $342345 | $(337) | $536713 | $879390 |
| &nbsp;&nbsp;Net loss |  |  |  |  | (5287) | (5287) |
| &nbsp;&nbsp;Issuance of shares upon exercise of stock options and vesting of restricted stock units | 2634942 | 3 | 224 |  |  | 227 |
| &nbsp;&nbsp;Share-based compensation expense |  |  | 3517 |  |  | 3517 |
| &nbsp;&nbsp;Unrealized gain on derivatives, net of tax expense of $52 |  |  |  | 139 |  | 139 |
| **Balance – March 31, 2026** | 671711593 | $672 | $346086 | $(198) | $531426 | $877986 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | | | | |
| | **Shares** | **Amount** |<br>**Additional Paid <br>in Capital** |<br>**Accumulated Other Comprehensive Loss** |<br>**Retained<br>Earnings** |<br>**Total Stockholders' Equity** |
| **Balance - December 31, 2024** | 664224893 | $664 | $328538 | $(765) | $545965 | $874402 |
| &nbsp;&nbsp;Net income |  |  |  |  | 465 | 465 |
| &nbsp;&nbsp;Issuance of shares upon exercise of stock options and vesting of restricted stock units | 1485913 | 2 | 525 |  |  | 527 |
| &nbsp;&nbsp;Share-based compensation expense |  |  | 2918 |  |  | 2918 |
| &nbsp;&nbsp;Unrealized gain on derivatives, net of tax expense of $4 |  |  |  | 17 |  | 17 |
| **Balance – March 31, 2025** | 665710806 | $666 | $331981 | $(748) | $546430 | $878329 |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

**OLAPLEX HOLDINGS, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS** 

*(amounts in thousands)*

*(Unaudited)*

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| **Cash flows from operating activities:** |  |  |
| Net (loss) income | $(5287) | $465 |
| Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of patent formulations | 2416 | 2392 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of other intangibles | 10820 | 10893 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory write-off and disposal | 203 | 1064 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation of fixed assets | 82 | 87 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt issuance costs | 287 | 453 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred taxes | (4360) | (95) |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation expense | 3517 | 2918 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 606 | 309 |
| Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | (8757) | (8882) |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory | (6493) | (5197) |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 46160 | (6350) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 21041 | 13836 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | (52476) | (12474) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets and liabilities | (260) | (2336) |
| Net cash provided by (used in) operating activities | 7499 | (2917) |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase of property and equipment | (146) | (48) |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase and development of software | (142) | (948) |
| Net cash used in investing activities | (288) | (996) |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from exercise of stock options | 227 | 527 |
| &nbsp;&nbsp;&nbsp;&nbsp;Principal payments of 2022 Term Loan Facility |  | (1688) |
| Net cash provided by (used in) financing activities | 227 | (1161) |
| Net increase (decrease) in cash and cash equivalents | 7438 | (5074) |
| Cash and cash equivalents - beginning of period | 318731 | 585967 |
| Cash and cash equivalents - end of period | $326169 | $580893 |
| **Supplemental disclosure of cash flow information:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash (refunded) paid for income taxes | $(2906) | $615 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $6775 | $13135 |
| **Supplemental disclosure of noncash activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of software not yet paid | $15 | $22 |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property and equipment not yet paid | $30 | $74 |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

**OLAPLEX HOLDINGS, INC.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS** 

*(in thousands, except share and per share amounts, percentages and as otherwise indicated)*

*(Unaudited)*

**NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION**

***Basis of Presentation***

The accompanying unaudited, interim Condensed Consolidated Financial Statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP" or "U.S. GAAP") with all intercompany balances and transactions eliminated, for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the "SEC"). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited, interim Condensed Consolidated Financial Statements furnished reflect all adjustments which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the full fiscal year. The unaudited, interim Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and accompanying footnotes included in the Company's 2025 Form 10-K, as filed with the SEC on March 5, 2026.

***Proposed Acquisition by Henkel US Operations Corporation***

On March 26, 2026, Olaplex Holdings entered into an Agreement and Plan of Merger (as it may be amended, modified or supplemented from time to time, the "Merger Agreement"), by and among Olaplex Holdings, Henkel US Operations Corporation, a Delaware corporation ("Parent"), and Margot Acquisition Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of conditions set forth therein, Merger Sub will merge with and into Olaplex Holdings, with Olaplex Holdings continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"), in accordance with the General Corporation Law of the State of Delaware ("DGCL").

The board of directors of Olaplex Holdings (the "Board") unanimously: (i) determined that the Merger Agreement and the Merger and the other transactions contemplated therein (collectively, the "Transactions") are advisable, fair to and in the best interests of Olaplex Holdings and its stockholders (the "Company Stockholders"), (ii) approved, adopted and declared advisable the entrance into and execution and delivery of the Merger Agreement and the Transactions, including the Merger, (iii) directed that the Merger Agreement be submitted to the Company Stockholders for its adoption and (iv) subject to the terms and conditions of the Merger Agreement, recommended that the Company Stockholders adopt the Merger Agreement.

The adoption of the Merger Agreement by the Company Stockholders required the affirmative vote or written consent by holders of a majority of the voting power of the outstanding shares of common stock, par value $0.001 per share, of Olaplex Holdings (the "Common Stock") entitled to vote thereon. On March 26, 2026, investment funds affiliated with Advent International Corporation (the "Principal Stockholders"), which held approximately 75% of the issued and outstanding shares of Common Stock as of such date, executed and delivered a written consent adopting the Merger Agreement. As a result, no further action by any Company Stockholder is required under applicable law or the Merger Agreement (or otherwise) to adopt the Merger Agreement.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

Pursuant to the Merger Agreement, (i) each share (a "Share" and collectively, the "Shares") of Common Stock issued and outstanding immediately prior to the date and time at which the Merger becomes effective (the "Effective Time") (other than those shares of Common Stock described in clauses (ii) and (iii) below) will be converted automatically into the right to receive $2.06 per Share (the "Merger Consideration"), payable net to the holder in cash, without interest, subject to any withholding of taxes required by applicable law as provided in the Merger Agreement, and all such Shares will no longer be outstanding and will automatically be cancelled and will cease to exist; (ii) each Share held by Olaplex Holdings as treasury stock or held directly by Parent or Merger Sub, or any direct or indirect wholly owned subsidiaries of Olaplex Holdings, Parent or Merger Sub, in each case, immediately prior to the Effective Time, shall automatically be cancelled and shall cease to exist, and no consideration or payment shall be delivered in exchange therefor or in respect thereof; and (iii) each Share issued and outstanding immediately prior to the Effective Time and held by a holder who is entitled to demand, and has properly demanded, appraisal for such Shares in accordance with, and who complies in all respects with, Section 262 of the DGCL (such shares, the "Dissenting Shares") shall not be converted into the right to receive the Merger Consideration, and such Shares shall be cancelled and cease to exist, and the holders of Dissenting Shares shall only be entitled to the rights granted to them under the DGCL with respect to such Dissenting Shares.

Pursuant to the Merger Agreement, at the Effective Time each outstanding Olaplex Holdings equity award will be treated as follows (in all cases, subject to applicable tax withholding):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• At the Effective Time, each option to purchase Shares granted under the Company's 2021 Equity Incentive Plan, the Company's Amended & Restated 2020 Omnibus Equity Incentive Plan and any other effective equity or equity-based incentive plan sponsored by the Company or any of its affiliates (each such option a "Company Option", and such equity or equity-based incentive plans, collectively, the "Company Equity Plans") that is outstanding and unexercised immediately prior to the Effective Time (whether vested or unvested) shall, by virtue of the Merger, automatically and without any required action on the part of the holder thereof, the Company or Parent be cancelled and converted into the right to receive (without interest) an amount in cash equal to the product of (x) the aggregate number of Shares underlying such Company Option multiplied by (y) the excess, if any, of the Merger Consideration over the per Share exercise price of such Company Option; provided, however, that any Company Option that has a per Share exercise price that is equal to or greater than the Merger Consideration shall be cancelled for no consideration; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• At the Effective Time, each award of restricted stock units covering Shares granted under the Company Equity Plans (each, a "Company RSU Award") that is outstanding immediately prior to the Effective Time (whether vested or unvested) shall, by virtue of the Merger, automatically and without any required action on the part of the holder thereof, the Company or Parent be cancelled and converted into the right to receive (without interest) an amount in cash equal to the product of (x) the aggregate number of Shares underlying such Company RSU Award multiplied by (y) the Merger Consideration.

The Merger Agreement contains customary representations, warranties and covenants that the Company must observe, including certain interim operating covenants that may restrict the Company's operations during the pendency of the Merger, subject to certain exceptions. In addition, the Merger Agreement contains certain termination rights that may require the Company to pay Parent a termination fee of $40,440,000 under certain circumstances. For additional details regarding the Merger and the terms thereof, refer to the Merger Agreement, a copy of which is incorporated by reference as an exhibit to this Quarterly Report.

The Merger is subject to customary closing conditions, including, without limitation, (i) twenty calendar days having elapsed since the Company mailed to its stockholders the information statement as contemplated by Regulation 14C of the Exchange Act, (ii) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), and approvals under the laws of Germany, Australia and the United Kingdom, and (iii) the absence of any law or governmental order prohibiting the Merger. The initial outside date for completion of the Merger is March 31, 2027, which may be extended to September 30, 2027 if, as of such initial date, all conditions to the closing of the Merger other than conditions relating to the HSR Act or other applicable antitrust and foreign direct investment laws have been satisfied or waived. The Company cannot predict with certainty, however, whether or when all the required closing conditions will be satisfied or if the Merger will close at all.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

Concurrently with the execution and delivery of the Merger Agreement, the Company entered into a limited waiver and amendment (the "Tax Receivable Agreement Waiver and Amendment") to the Tax Receivable Agreement, pursuant to which certain Tax Receivable Agreement parties irrevocably waived their rights to receive any remaining payments under the Tax Receivable Agreement, and the Tax Receivable Agreement was amended to provide for its automatic termination upon the Effective Time, subject to the payment of certain amounts to non-waiving Tax Receivable Agreement parties. If the Merger Agreement is terminated in accordance with its terms, the Tax Receivable Agreement Waiver and Amendment will be null and void ab initio and all obligations under the Tax Receivable Agreement will continue in full force and effect.

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

***Estimates and Assumptions***

Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Examples of estimates and assumptions include: for revenue recognition, determining the nature and timing of satisfaction of performance obligations, variable consideration, and other obligations such as product returns, allowance for promotions, and refunds; loss contingencies; the fair value of and/or potential impairment of goodwill and intangible assets for the Company's reporting unit; useful lives of the Company's tangible and intangible assets; estimated income tax expense and tax payments; future payment obligations under the Tax Receivable Agreement; and the net realizable value of, and demand for the Company's inventory. Actual results and outcomes may differ from management's estimates and assumptions due to risks and uncertainties.

***Fair Value of Financial Instruments***

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The authoritative guidance for fair value measurements established a framework for measuring fair value and established a three-level valuation hierarchy for disclosure of fair value measurements as follows:

***Level 1***—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. The Company's Level 1 assets consist of its marketable securities.

***Level 2***—Observable quoted prices for similar assets or liabilities in active markets and observable quoted prices for identical assets or liabilities in markets that are not active.

***Level 3***—Unobservable inputs that are not corroborated by market data.

Cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are reflected at carrying value, which approximates fair value due to the short-term maturity. The Company's long-term debt is recorded at its carrying value in the Condensed Consolidated Balance Sheets, which may differ from fair value. The Company's 2024 Interest Rate Cap (as defined in "Note 5 – Fair Value Measurement" to the Company's Condensed Consolidated Financial Statements of this Quarterly Report) is recorded at its Level 2 fair value in the Condensed Consolidated Balance Sheets.

***Accounting Policies***

There have been no material changes in significant accounting policies as described in the Company's Consolidated Financial Statements for the year ended December 31, 2025.

***Tax Receivable Agreement***

In connection with the Reorganization Transactions, the Company entered into the Tax Receivable Agreement under which the Company will be required to pay to the Pre-IPO Stockholders 85% of the federal, state or local tax cash savings that the Company actually realizes on its taxable income following the IPO, as a result of the amortization of intangible assets and capitalized transaction costs that existed as of the date of the IPO. Under the Tax Receivable Agreement, generally the Company will retain the benefit of the remaining 15% of the applicable tax savings.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

The Tax Receivable Agreement liability is calculated based on current tax laws and the assumption that the Company and its subsidiaries will earn sufficient taxable income to realize the full tax benefits subject to the Tax Receivable Agreement. Updates to the Company's blended state tax rate, allocation of U.S. versus foreign sourced income and changes in U.S. tax rules may significantly impact the established liability, and any changes to that established liability would be recorded to Other expense (income), net in the period in which the Company makes the determination regarding the applicable change.

Concurrently with the execution and delivery of the Merger Agreement, the Company entered into the Tax Receivable Agreement Waiver and Amendment, pursuant to which certain Pre-IPO Stockholders irrevocably waived their rights to receive any remaining payments under the Tax Receivable Agreement. In addition, the Tax Receivable Agreement was amended to provide for its automatic termination upon the Effective Time, subject to the payment of certain amounts to non-waiving Pre-IPO Stockholders. If the Merger Agreement is terminated in accordance with its terms, the Tax Receivable Agreement Waiver and Amendment will be null and void ab initio and all obligations under the Tax Receivable Agreement will continue in full force and effect. See further discussion in "Note 1 – Nature of Operations and Basis of Presentation – Proposed Acquisition by Henkel US Operations Corporation" to the Company's Condensed Consolidated Financial Statements of this Quarterly Report.

If the Merger Agreement is terminated and as a result the Tax Receivable Agreement Waiver and Amendment becomes null and void, the Company expects that future payments under the Tax Receivable Agreement relating to the Pre-IPO Tax Assets could aggregate to $165.1 million, with payments expected to continue through 2038. Payments under the Tax Receivable Agreement, which began in the year ended December 31, 2022, are not conditioned upon the Pre-IPO Stockholders' continued ownership of equity in the Company.

***Recently Adopted Accounting Pronouncements***

In July 2025, the FASB issued ASU No. 2025-05, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets" which introduces a practical expedient for all entities to simplify the calculation required for applying credit losses to current accounts receivable, by assuming current conditions as of the balance sheet date do not change for the remaining life of the asset. The new guidance is effective for fiscal years beginning after December 15, 2025 and interim periods within fiscal years beginning after December 15, 2025. The Company adopted ASU 2025-05 on a prospective basis effective January 1, 2026 with no material impact on its Consolidated Financial Statements and related disclosures.

***Recent Accounting Pronouncements Not Yet Adopted***

In November 2024, the FASB issued ASU No. 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses" which is intended to improve the disclosures about a public business entity's expenses by requiring disaggregated disclosure of certain income statement expense captions into specified categories in the notes to the financial statements. The new guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The Company expects this update to impact its disclosures in the notes to its financial statements but does not anticipate any effect on its Consolidated Results of Operations, Cash Flows or financial condition.

In September 2025, the FASB issued ASU No. 2025-06. "Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software" which amends the existing standard, which refers to various stages of a software development project, to align better with current software development methods. Under the new standard, entities will start capitalizing eligible costs when (1) management has authorized and committed to funding the software project, and (2) it is probable that the project will be completed and the software will be used to perform the function intended. The new guidance is effective for fiscal years beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. The Company is currently evaluating the potential impact of adopting this new guidance on its Consolidated Financial Statements and related disclosures.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

**NOTE 3 – NET SALES**

The Company distributes products in the U.S. and internationally through professional distributors in salons ("professional"), directly to retailers for sale in their physical stores and e-commerce sites ("specialty retail"), and direct-to-consumer ("DTC") through sales to third party e-commerce customers and through its own Olaplex.com website. During the three months ended March 31, 2026 and March 31, 2025, the Company's net sales by its three sales channels, professional, specialty retail and DTC, were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended**<br>**March 31,** | **Three Months Ended**<br>**March 31,** |
| | **2026** | **2025** |
| **Net sales by Channel:** |  |  |
| Professional | $38785 | $34538 |
| Specialty retail | 33411 | 38553 |
| DTC | 27173 | 23887 |
| &nbsp;&nbsp;Total net sales | $99369 | $96978 |

---

Net sales by major geographic region are based on the shipping address on record for the customer purchasing the Company's products. During the three months ended March 31, 2026 and March 31, 2025, the Company's net sales to consumers in the United States and International regions were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended**<br>**March 31,** | **Three Months Ended**<br>**March 31,** |
| | **2026** | **2025** |
| **Net sales by Geography:** |  |  |
| United States | $47436 | $49161 |
| International | 51933 | 47817 |
| &nbsp;&nbsp;Total net sales | $99369 | $96978 |

---

No international country exceeded 10% of total net sales for the three months ended March 31, 2026 and March 31, 2025. Regardless of our customers' geographic location, the majority of net sales are transacted in U.S. Dollars, the Company's functional and reporting currency.

**NOTE 4 – INVENTORY**

Inventory as of March 31, 2026 and December 31, 2025 consisted of the following:

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| Raw materials | $15683 | $15335 |
| Finished goods | 50681 | 44880 |
| Inventory | $66364 | $60215 |

---

As of March 31, 2026 and December 31, 2025, the Company's allowance for excess and obsolete inventory was $14.3 million and $14.1 million, respectively.

During the three months ended March 31, 2026 and March 31, 2025, the Company recorded inventory write-offs of $0.2 million and $1.1 million, respectively, due to reserves for product obsolescence.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

**NOTE 5 – FAIR VALUE MEASUREMENT**

Fair value measurements are established utilizing a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets; Level 2, defined as observable quoted prices for similar assets or liabilities in active markets and observable quoted prices for identical assets or liabilities in markets that are not active; and Level 3, defined as unobservable inputs that are not corroborated by market data. The Company's Level 1 assets consist of its marketable securities. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

On May 7, 2024, the Company entered into an interest rate cap transaction (the "2024 Interest Rate Cap") in connection with the 2022 Term Loan Facility, with a notional amount of $400.0 million, which amortized to $200.0 million on July 31, 2025, at a strike rate of 5.00%. The 2024 Interest Rate Cap expires on July 31, 2026.

The 2024 Interest Rate Cap is measured at fair value on a recurring basis by a third-party specialist using widely accepted valuation techniques. The fair value of the 2024 Interest Rate Cap is determined using a modification of the Black's model, known as the shifted lognormal model. The variable interest rates used in the calculation are based on future interest rates derived from observable market interest rate curves and volatilities. The specialist incorporates credit valuation adjustments to appropriately reflect the respective counterparty's nonperformance risk in the fair value measurements. Although the Company has determined that the majority of the inputs used to value the 2024 Interest Rate Cap fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with the 2024 Interest Rate Cap utilize Level 3 inputs. The Company has determined that the impact of the credit valuation adjustments made to the 2024 Interest Rate Cap were not significant to the overall valuation. As a result, the 2024 Interest Rate Cap as of March 31, 2026 and December 31, 2025 was classified as Level 2 of the fair value hierarchy. The fair value of the 2024 Interest Rate Cap was de minimis as of March 31, 2026 and December 31, 2025.

The Company's assets measured at fair value on a recurring basis and subject to fair value disclosure requirements at March 31, 2026 were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Total** | **Level 1** | **Level 2** | **Level 3** |
| **Assets:** | | | | |
| Cash and cash equivalents: |  |  |  |  |
| &nbsp;&nbsp;Money market funds | $11641 | $11641 | $— | $— |

---

The Company's assets measured at fair value on a recurring basis and subject to fair value disclosure requirements at December 31, 2025 were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Total** | **Level 1** | **Level 2** | **Level 3** |
| **Assets:** | | | | |
| Cash and cash equivalents: |  |  |  |  |
| &nbsp;&nbsp;Money market funds | $11536 | $11536 | $— | $— |

---

**NOTE 6 – GOODWILL AND INTANGIBLE ASSETS**

Goodwill and intangible assets as of March 31, 2026 and December 31, 2025 were comprised of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
| | **Estimated<br>Useful Life** | **Gross Carrying <br>Amount** | **Accumulated <br>Amortization** | **Net Carrying** <br>**Amount** |
| Brand name | 25 years | $952000 | $(237153) | $714847 |
| Product formulations | 15 years | 136500 | (56556) | 79944 |
| Customer relationships | 20 years | 53000 | (16507) | 36493 |
| Software | 3-7 years | 11355 | (7775) | 3580 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total finite-lived intangibles |  | 1152855 | (317991) | 834864 |
| Goodwill | Indefinite | 168300 |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;168300 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total goodwill and other intangibles |  | $1321155 | $(317991) | $1003164 |

---

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| | **Estimated<br>Useful Life** | **Gross Carrying Amount** | **Accumulated <br>Amortization** | **Net Carrying** <br>**Amount** |
| Brand name | 25 years | $952000 | $(227636) | $724364 |
| Product formulations | 15 years | 136500 | (54281) | 82219 |
| Customer relationships | 20 years | 53000 | (15841) | 37159 |
| Software | 3-7 years | 11217 | (7138) | 4079 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total finite-lived intangibles |  | 1152717 | (304896) | 847821 |
| Goodwill | Indefinite | 168300 |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;168300 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total goodwill and other intangibles |  | $1321017 | $(304896) | $1016121 |

---

The amortization of the Company's brand name, customer relationships and software is recorded to Amortization of other intangible assets in the Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income. A portion of Amortization of patented formulations is capitalized to Inventory in the Condensed Consolidated Balance Sheets, and the remainder is recorded to Amortization of patented formulations in the Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income.

Amortization of the Company's definite-lived intangible assets for the three months ended March 31, 2026 and 2025 was as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** <br>**March 31,** | **Three Months Ended** <br>**March 31,** |
| | **2026** | **2025** |
| Amortization expense, patented formulations | $2416 | $2392 |
| Amortization expense, brand name and customer relationships | 10183 | 10182 |
| Amortization expense, software | 637 | 711 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization expense, other intangible assets | $10820 | $10893 |
| Amortization expense, patented formulations capitalized to inventory | $(141) | $(118) |

---

**NOTE 7 – ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES**

Accrued expenses as of March 31, 2026 and December 31, 2025 consisted of the following:

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| Sales tax payable | $1034 | $2814 |
| Accrued professional fees | 11484 | 5371 |
| Payroll liabilities | 5272 | 10314 |
| Accrued freight | 2289 | 3904 |
| Accrued advertising | 6213 | 9873 |
| Deferred revenue | 1256 | 925 |
| Income tax payable | 294 | 243 |
| Accrued promotional allowance | 116 | 143 |
| Accrued *Lilien* legal settlement |  | 46126 |
| Other accrued expenses and current liabilities | 4800 | 5591 |
| Accrued expenses and other current liabilities | $32758 | $85304 |

---

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

As of December 31, 2025, the Company accrued approximately $46.1 million related to a pending settlement of the *Lilien* matter. The Company expected to recover substantially all of this settlement amount under its insurance policy and, as such, an insurance receivable of $46.8 million was recorded in Prepaid expenses and other current assets in the Consolidated Balance Sheets as of December 31, 2025. As the appeals process expired in January 2026 and the judgment is now final, the Company released the accrued balance and related insurance receivable during the three months ended March 31, 2026. See further discussion regarding the *Lilien* matter in "Note 12 – Commitments and Contingencies" to the Company's Condensed Consolidated Financial Statements of this Quarterly Report.

**NOTE 8 – LONG-TERM DEBT**

The Company's Long-Term Debt as of March 31, 2026 and December 31, 2025 consisted of the following:

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| **Long-term debt** | | |
| &nbsp;&nbsp;&nbsp;*Credit Agreement, dated as of February 23, 2022 (the "2022 Credit Agreement")* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$675 Million 7-Year Senior Secured Term Loan Facility (the "2022 Term Loan Facility") | $354750 | $354750 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$150 Million 5-Year Senior Secured Revolving Credit Facility (the "2022 Revolver")<sup>(1)</sup> |  |  |
| Debt issuance costs | (2266) | (2460) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total term loan debt | 352484 | 352290 |
| Less: Current portion |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Long-term debt, net of debt issuance costs and current portion | $352484 | $352290 |

---

<sup>(1)</sup> As of March 31, 2026 and December 31, 2025, the Company did not have any outstanding amounts drawn on the 2022 Revolver, including letters of credit and swingline loan sub-facilities. As of March 31, 2026, the Company had $150 million of available borrowing capacity under the 2022 Revolver.

The 2022 Credit Agreement contains a number of covenants that, among other things, restrict Olaplex, Inc.'s ability to (subject to certain exceptions) (i) pay dividends and distributions or repurchase its capital stock, (ii) prepay, redeem, or repurchase certain indebtedness, (iii) incur additional indebtedness and guarantee indebtedness, (iv) create or incur liens, (v) engage in mergers, consolidations, liquidations or dissolutions, (vi) sell, transfer or otherwise dispose of assets, (vii) make investments, acquisitions, loans or advances and (viii) enter into certain transactions with affiliates. The 2022 Credit Agreement also includes, among other things, customary affirmative covenants (including reporting covenants) and events of default (including a change of control) for facilities of this type, subject to certain exceptions and thresholds set forth in the 2022 Credit Agreement. In addition, the 2022 Credit Agreement includes a springing first lien leverage ratio financial covenant, which is applicable only to the lenders under the 2022 Revolver. The Company was in compliance with these affirmative and negative covenants as of March 31, 2026. The 2022 Term Loan Facility and the 2022 Revolver are secured by substantially all of the assets of Olaplex, Inc. and the other guarantors, subject to certain exceptions and thresholds.

The interest rate on outstanding debt under the 2022 Term Loan Facility was 7.3% per annum as of March 31, 2026. The interest rates for all facilities under the 2022 Credit Agreement are calculated based upon the Company's election among (a) adjusted term secured overnight financing rate ("SOFR") (subject to a 0.50% floor with respect to the 2022 Term Loan Facility, and a 0% floor with respect to the 2022 Revolver) plus an additional interest rate spread, (b) with respect to a borrowing in Euros under the 2022 Revolver, a euro interbank offered rate (subject to a 0% floor) plus an additional interest rate spread, or (c) an "Alternate Base Rate" (as defined in the 2022 Credit Agreement) (subject to a 1.50% floor with respect to the 2022 Term Loan Facility, and a 1.00% floor with respect to the 2022 Revolver) plus an additional interest rate spread.

Interest expense, inclusive of amortization of debt issuance costs, for the three months ended March 31, 2026 and March 31, 2025 was $7.1 million and $13.7 million, respectively.

The fair value of the Company's long-term debt is based on the market value of its long-term debt instrument. Based on the inputs used to value the long-term debt, the Company's long-term debt is categorized within Level 2 in the fair value hierarchy. As of March 31, 2026, the carrying amount, excluding debt issuance costs, and estimated fair value of the Company's long-term debt was $354.8 million and $355.2 million, respectively. As of December 31, 2025, the carrying amount, excluding debt issuance costs, and estimated fair value of the Company's long-term debt was $354.8 million and $343.2 million, respectively.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

***Interest Rate Cap***

The Company's results are subject to risk from interest rate fluctuations on borrowings under the 2022 Credit Agreement, including the 2022 Term Loan Facility. The Company may, from time to time, utilize interest rate derivatives in an effort to add stability to interest expense and to manage its exposure to interest rate fluctuations. See further discussion in "Note 5 – Fair Value Measurement" to the Company's Condensed Consolidated Financial Statements of this Quarterly Report.

During the three months ended March 31, 2026, the Company's 2024 Interest Rate Cap generated a $0.2 million unrecognized pre-tax gain, recorded in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets. During the same period, the Company also recognized $0.2 million of interest expense related to amortization of the 2024 Interest Rate Cap premium paid by the Company.

During the three months ended March 31, 2025, the Company's 2024 Interest Rate Cap generated an immaterial unrecognized pre-tax gain, recorded in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets. During the same period, the Company also recognized $0.2 million of interest expense related to amortization of the 2024 Interest Rate Cap premium paid by the Company.

The Company performed an initial effectiveness assessment on the 2024 Interest Rate Cap and determined it to be an effective hedge of the cash flows related to the interest rate payments on the 2022 Term Loan Facility. The hedge is evaluated qualitatively on a quarterly basis for effectiveness. For derivatives designated, and that qualify, as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated other comprehensive income (loss) and subsequently reclassified into Interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company's accounting policy election. Payment of the up-front premium of the 2024 Interest Rate Cap is included within prepaid expenses and other current assets and other assets and liabilities within the cash flows from operating activities on the Company's Condensed Consolidated Statements of Cash Flows.

The Company does not hold or issue derivative financial instruments for trading purposes, nor does it hold or issue leveraged derivative instruments. By using derivative financial instruments to hedge exposures to interest rate fluctuations, the Company exposes itself to counterparty credit risk. The Company manages exposure to counterparty credit risk by entering into derivative financial instruments with highly rated institutions that can be expected to fully perform under the terms of the applicable contracts.

**NOTE 9 – INCOME TAXES**

The Company's effective tax rate was 45.4% for the three months ended March 31, 2026, as compared to 47.2% for the three months ended March 31, 2025.

The effective tax rate for the three months ended March 31, 2026 was higher than the statutory rate of 21% primarily due to the unfavorable impact of non-deductible stock compensation and the effect of state income taxes.

The effective tax rate for the three months ended March 31, 2025 was higher than the statutory rate of 21% primarily due to discrete tax expenses for a change in prior year estimates, write-off of deferred tax assets associated with net shortfalls upon vesting of restricted stock units, forfeitures of non-qualified stock options and restricted stock units and the impact of those items on the lower book income for the three months ended March 31, 2025.

**NOTE 10 – EQUITY**

During the three months ended March 31, 2026, the Company issued 2,634,942 shares of its common stock, of which 297,945 shares were issued as a result of stock options exercised and 2,336,997 shares were issued upon vesting of restricted stock units.

During the three months ended March 31, 2025, the Company issued 1,485,913 shares of its common stock, of which 692,681 shares were issued as a result of stock options exercised and 793,232 shares were issued upon vesting of restricted stock units.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

**NOTE 11 – RELATED PARTY TRANSACTIONS**

*Tax Receivable Agreement*

In connection with the Reorganization Transactions, the Company entered into the Tax Receivable Agreement with the Pre-IPO Stockholders. See further discussion in "Note 2 – Summary of Significant Accounting Policies – Tax Receivable Agreement" to the Company's Condensed Consolidated Financial Statements of this Quarterly Report.

Concurrently with the execution and delivery of the Merger Agreement, the Company entered into the Tax Receivable Agreement Waiver and Amendment, pursuant to which certain Pre-IPO Stockholders irrevocably waived their rights to receive any remaining payments under the Tax Receivable Agreement. In addition, the Tax Receivable Agreement was amended to provide for its automatic termination upon the Effective Time, subject to the payment of certain amounts to non-waiving Pre-IPO Stockholders. See further discussion in "Note 1 – Nature of Operations and Basis of Presentation – Proposed Acquisition by Henkel US Operations Corporation" to the Company's Condensed Consolidated Financial Statements of this Quarterly Report.

The Company did not make any payments pursuant to the terms of the Tax Receivable Agreement during either the three months ended March 31, 2026 or 2025.

**NOTE 12 – COMMITMENTS AND CONTINGENCIES**

***Commitments***

Purchase commitments are comprised of the Company's commitments for contracted goods and services arising in the ordinary course of business. These commitments are generally short-term in nature and are recorded as liabilities when the related goods are received or services rendered.

***Contingencies***

From time to time, the Company is subject to various legal actions arising in the ordinary course of business. The Company cannot predict with reasonable assurance the outcome of these legal actions brought against the Company as they are subject to uncertainties. Accordingly, any settlement or resolution of these legal actions may occur and affect the Company's net income in the period in which the settlement or resolution occurs.

***Pending Legal Proceedings***

On November 17, 2022, a putative securities class action was filed against the Company and certain of its current and former officers and directors in the United States District Court for the Central District of California, captioned *Lilien v. Olaplex Holdings, Inc. et al.*, No. 2:22-cv-08395. The action was brought on behalf of a putative class of purchasers of the Company's common stock in or traceable to the Company's IPO and asserted claims under Sections 11, 12, and 15 of the Securities Act of 1933. After the court's decision denying defendants' motion to dismiss in part and the parties' briefing on class certification, on July 2, 2025, the parties filed a joint stipulation notifying the court that they had reached an agreement in principle to settle the action on a class-wide basis. On December 5, 2025, the court approved the settlement, and the appeals period expired in January 2026. The judgment is now final. The Company continues to expressly deny any charges or allegations of wrongdoing or liability arising out of any of the conduct, statements, acts, or omissions alleged in the action.

On November 15, 2023, a purported derivative action was filed against the Company, Advent International Corporation, and certain of the Company's current and former officers and directors in the United States District Court for the Central District of California, captioned *Ciuffo v. Dagousset*, et al., No. 2:23-cv-09712-SVW-SK. This action is premised on allegations similar to those asserted in the *Lilien* federal securities litigation. Plaintiffs seek declaratory and injunctive relief, as well as an award of monetary damages and attorneys' fees. On February 1, 2024, the parties filed a joint stipulation to stay the purported derivative action pending a decision on the motions to dismiss filed in the *Lilien* federal securities action.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

On March 22, 2024, a second purported derivative action was filed against the Company, Advent International Corporation, and certain of the Company's current and former officers and directors in the United States District Court for the Central District of California, captioned *Hutchinson v. Advent International Corporation, et al*., No. 2:24-cv-02364. This action is premised on allegations similar to those asserted in the *Lilien* federal securities litigation and in the *Ciuffo* federal derivative action and seeks similar relief to that sought in *Ciuffo*. On April 19, 2024, the parties in both purported derivative actions filed a joint stipulation to consolidate the two derivative actions into the first filed docket (No. 2:23 cv-09712-SVW-SK), and to stay proceedings in the consolidated case, which the court granted on June 26, 2024. On March 17, 2025, the court held a status conference with the parties, during which the court ordered that the stay in the action shall remain in effect pending resolution of the *Lilien* action. On May 28, 2025, the court entered an order lifting the stay as to the master file and restoring it to the active calendar, while ordering that all consolidated derivative actions are stayed and moved into the inactive calendar. On February 23, 2026, the parties filed a notice of settlement with the court that indicated that the parties reached a binding settlement agreement that resolves the derivative claims, subject to court approval. The parties requested that the court set a deadline to file the motion for preliminary approval of the settlement and confirm a stay of the proceedings. On February 25, 2026, the court approved the parties' request and moved the matter to the inactive calendar pending finalization of the settlement. On April 24, 2026, the parties executed a settlement agreement, and plaintiffs filed their motion for preliminary approval of the settlement. On May 7, 2026, the court granted the motion for preliminary approval of the settlement.

Any potential loss associated with these pending legal proceedings is not probable or reasonably estimable at this time.

As of March 31, 2026, the Company was not subject to any other currently pending legal matters or claims that could have a material adverse effect on its financial position, results of operations, or cash flows should such litigation be resolved unfavorably.

**NOTE 13 – NET (LOSS) INCOME PER SHARE**

The following is a reconciliation of the numerator and denominator in the basic and diluted net (loss) income per common share computations:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended**<br>**March 31,** | **Three Months Ended**<br>**March 31,** |
| | **2026** | **2025** |
| **Numerator:** |  |  |
| Net (loss) income | $(5287) | $465 |
| **Denominator:** |  |  |
| Weighted average common shares outstanding – basic | 669942446 | 664685462 |
| Dilutive common equivalent shares from equity options and awards |  | 1775252 |
| Weighted average common shares outstanding – diluted | 669942446 | 666460714 |
| **Net (loss) income per share:** |  |  |
| Basic | $(0.01) | $0.00 |
| Diluted | $(0.01) | $0.00 |

---

The shares of the Company's common stock underlying stock options, restricted stock units and stock settled stock appreciation rights ("SARs") that were excluded in the computation of diluted net (loss) income per common share because their inclusion would have been anti-dilutive were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended**<br>**March 31,** | **Three Months Ended**<br>**March 31,** |
| | **2026** | **2025** |
| Stock options | 9289833 | 8891906 |
| Restricted stock units | 21356362 | 10964556 |
| SARs |  | 39555 |

---

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

**NOTE 14 – SEGMENT REPORTING**

The Company sells haircare products through three sales channels: professional, specialty retail and DTC. The Company does not have intersegment revenues. See further discussion in "Note 3 – Net Sales" to the Company's Condensed Consolidated Financial Statements of this Quarterly Report for more information. The Company manages its business on the basis of its three sales channels that are part of a single operating segment and, therefore, a single reportable segment.

The Company's chief operating decision maker ("CODM") is its Chief Executive Officer. The CODM assesses the Company's performance based on net income that is also reported on the Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income. The measure of the Company's segment assets is reported on the Condensed Consolidated Balance Sheets as total assets.

The CODM uses net income to evaluate income generated from segment assets in deciding how to reinvest profits into the Company as well as in assessing performance of the segment.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended**<br>**March 31,** | **Three Months Ended**<br>**March 31,** |
| | **2026** | **2025** |
| Net sales | $99369 | $96978 |
| Less: <sup>(1)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of product (excluding amortization) | 25293 | 27230 |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketing expenses | 26036 | 18111 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted selling, general, and administrative <sup>(2)</sup> | 27828 | 25553 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 13318 | 13372 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 7132 | 13725 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | (2702) | (5952) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax (benefit) provision | (4396) | 416 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation expense | 3517 | 2918 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other segment items <sup>(3)</sup> | 8630 | 1140 |
| Net (loss) income | $(5287) | $465 |

---

<sup>(1)</sup> The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.

<sup>(2)</sup> Amounts exclude depreciation and amortization expense, marketing expenses, share-based compensation expense and the other costs described in footnote 3 to this table.

<sup>(3)</sup> For the three months ended March 31, 2026, other segment items included $7.4 million of Merger transaction-related costs, research and development costs and Other expense (income), net. For the three months ended March 31, 2025, other segment items included research and development costs and Other expense (income), net.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

**ITEM 2 – MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited, interim Condensed Consolidated Financial Statements and related notes included elsewhere in this Quarterly Report and with our audited Consolidated Financial Statements included in the 2025 Form 10-K.*

*Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business and our proposed acquisition by Henkel US Operations Corporation, includes forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from management's expectations as a result of various factors. Factors that could cause or contribute to these differences include, but are not limited to, those identified below and those discussed in the section "Special Note Regarding Forward-Looking Statements" in this Quarterly Report and in "Item 1A. - Risk Factors" in this Quarterly Report and in the 2025 Form 10-K.*

***Company Overview***

In 2014, OLAPLEX revolutionized the haircare category through the introduction of our patent-protected bond-building technology, Bis-aminopropyl diglycol dimaleate ("Bis-amino"), in our No. 1 Bond Multiplier® and No. 2 Bond Perfector® products. This new two-part salon treatment allowed Pros around the world to repair disulfide bonds deep inside the hair that are broken during chemical services (such as coloring, perming and straightening). Later in 2014, OLAPLEX launched an at-home version of this signature bond-building treatment, No. 3 Hair Perfector®, allowing consumers to achieve the benefits of OLAPLEX beyond the salon. By the end of 2015, OLAPLEX products were sold globally, demonstrating the relevance of the product and brand proposition around the world. From our original three bond-building products, we expanded to a range of products suitable across hair types for use in the salon and at home.

Since our inception, we have focused on delivering patent-protected technology and proven performance in the prestige haircare category. From our origins of creating the bond-building space, our product portfolio has expanded to approximately 30 products that support the hair health needs of our Pro and consumer communities.

Our synergistic omnichannel model leverages the strength of each of our channels and our strong digital capabilities, which we apply across all of our sales platforms. Our professional channel serves as the foundation for our brand. Through this channel, Pros introduce consumers to our products and, we believe, influence consumer purchasing decisions. Our specialty retail channel allows us to build our brand by reinforcing our relationship with current consumers and accessing new consumers. Our DTC channel, comprised of Olaplex.com and sales through third-party e-commerce platforms, further broadens our access to consumers, while allowing us to directly engage with and educate consumers through our owned platforms.

***Proposed Acquisition by Henkel US Operations Corporation***

On March 26, 2026, Olaplex Holdings entered into an Agreement and Plan of Merger (as it may be amended, modified or supplemented from time to time, the "Merger Agreement"), by and among Olaplex Holdings, Henkel US Operations Corporation, a Delaware corporation ("Parent"), and Margot Acquisition Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Upon the terms and subject to the conditions of the Merger Agreement, Merger Sub will merge with and into Olaplex Holdings, with Olaplex Holdings continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). If the Merger is completed, each share of common stock, par value $0.001 per share, of Olaplex Holdings (the "Common Stock") issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time") (subject to certain exceptions described in "Note 1 – Nature of Operations and Basis of Presentation – Proposed Acquisition by Henkel US Operations Corporation" to the Company's Condensed Consolidated Financial Statements of this Quarterly Report) will be converted into the right to receive $2.06 per share in cash, without interest, subject to applicable withholding taxes.

The Merger Agreement contains customary representations, warranties and covenants that we must observe, including certain interim operating covenants that may restrict our operations during the pendency of the Merger, subject to certain exceptions. In addition, the Merger Agreement contains certain termination rights that may require us to pay Parent a $40,440,000 termination fee under certain circumstances. For additional details of the Merger and the terms thereof, refer to the Merger Agreement, a copy of which is incorporated by reference as an exhibit to this Quarterly Report.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

The Merger is presently expected to close as soon as the second half of 2026, subject to customary closing conditions, including, without limitation, (i) twenty calendar days having elapsed since we mailed to our stockholders the information statement as contemplated by Regulation 14C of the Exchange Act, (ii) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), and approvals under the laws of Germany, Australia and the United Kingdom, and (iii) the absence of any law or governmental order prohibiting the Merger. The initial outside date for completion of the Merger is March 31, 2027, which may be extended to September 30, 2027 if, as of such initial date, all conditions to the closing of the Merger other than conditions relating to the HSR Act or other applicable antitrust and foreign direct investment laws have been satisfied or waived. We cannot predict with certainty, however, whether or when all the required closing conditions will be satisfied or if the Merger will close at all.

**Our Strategy**

Following the initial implementation of our "Bonds and Beyond" vision in 2025, we are focused on the following three strategic priorities in 2026 aimed at accelerating our transformation.

***Energize our "Hero" Products***

We seek to implement our 360-degree marketing engine to maximize the productivity of our core products, which are significant contributors to our brand health and business. In addition, we are upgrading and expanding the assortment of our core products. Through targeted marketing strategies and enhanced storytelling, we are focused on continuing to elevate our brand and enhancing brand loyalty to generate demand.

***Fuel Science-based Innovation***

Olaplex's heritage includes a focus on bringing technical solutions to real-world hair concerns, and in 2026, we remain focused on expanding our product portfolio with science-based innovation. We have refined our research and development and new product development processes to prioritize innovation that seeks to address specific, meaningful consumer and Pro needs. We seek to deliver targeted, science-backed solutions that simplify the user experience and achieve visible results, and we expect to launch more innovations in 2026 than in 2025. In addition, we are pursuing growth in new verticals that we consider natural extensions of our existing product portfolio.

***Expand our Diversified, Scalable Go-to-market Model***

We are focused on sharpening our execution to support our Bonds and Beyond vision. We seek to capitalize on renewed momentum in our Professional channel, providing our Pro partners with tools and support to serve as powerful ambassadors for our brand. We are also deepening our point-of-sale partnerships, tailoring our brand marketing strategies and utilizing key promotional windows aimed at driving visibility while protecting our premium positioning. We will continue to focus on executing our three-tiered international strategy, prioritizing high-potential regions and improving local execution as we seek to scale our global reach in a disciplined, repeatable way. Finally, we aim to optimize our points of access to meet our consumers where they shop and maintain brand integrity as we extend our global footprint.

**Business Environment & Trends**

We continue to monitor the effects of the global macro-economic environment, including the risk of recession, inflationary pressures, competitive products and discounting, currency volatility, high interest rates, social and political issues, geopolitical tensions, regulatory matters and changes to tariffs and trade policies of the United States and other countries. Based on policies in place as of the date of filing of this Quarterly Report, we expect the most recent changes in tariffs and trade policies will have a relatively modest impact on our business since the vast majority of our products sold in the U.S. are sourced and manufactured domestically. However, related uncertainties could impact consumer discretionary spending, demand for our products, and ordering patterns and inventory practices at our customers. We also are mindful of inflationary pressures on our consumers amidst an increasingly competitive industry, and we are monitoring the impact that consumer confidence may have on consumer spending at our customers.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

Competition in the beauty industry is based on a variety of factors, including innovation, product efficacy, pricing, brand recognition and loyalty, service to the consumer, promotional activities, advertising, special events, new product introductions, e-commerce initiatives, sustainability and other activities. We have seen increased competitive activity including discounting in the prestige haircare category. We believe we have a well-recognized and strong reputation within the beauty industry, from our customers to the end-consumer, and that the quality and performance of our products, our emphasis on science-based innovation, our asset-light operating model, and our engagement with our Pro and consumer communities position us to compete effectively.

**Results of operations**

***Comparison of the Three Months Ended March 31, 2026 to the Three Months Ended March 31, 2025***

The following table sets forth our consolidated results for each of the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2026** | **2025** | **2025** |
| | **(in thousands)** | **% of net sales** | **(in thousands)** | **% of net sales** |
| Net sales | $99369 | 100.0% | $96978 | 100.0% |
| Cost of sales: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of product (excluding amortization) | 25293 | 25.5 | 27230 | 28.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of patented formulations | 2416 | 2.4 | 2392 | 2.5 |
| Total cost of sales | 27709 | 27.9 | 29622 | 30.5 |
| Gross profit | 71660 | 72.1 | 67356 | 69.5 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general, and administrative | 65951 | 66.4 | 47987 | 49.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of other intangible assets | 10820 | 10.9 | 10893 | 11.2 |
| Total operating expenses | 76771 | 77.3 | 58880 | 60.7 |
| Operating (loss) income | (5111) | (5.1) | 8476 | 8.7 |
| Interest expense | 7132 | 7.2 | 13725 | 14.2 |
| Interest income | (2702) | (2.7) | (5952) | (6.1) |
| Other expense (income), net | 142 | 0.1 | (178) | (0.2) |
| (Loss) Income before provision for income taxes | (9683) | (9.7) | 881 | 0.9 |
| Income tax (benefit) provision | (4396) | (4.4) | 416 | 0.4 |
| Net (loss) income | $(5287) | (5.3)% | $465 | 0.5% |

---

*Net Sales*

We distribute products in the U.S. and internationally through professional distributors in salons, directly to retailers for sale in their physical stores and on their e-commerce sites, and DTC through sales to third party e-commerce customers and through our Olaplex.com websites. As such, net sales by our three sales channels consisting of professional, specialty retail and DTC were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***(in thousands)*** | **Three Months Ended**<br>**March 31,** | **Three Months Ended**<br>**March 31,** | | |
|  | **2026** | **2025** | **$ Change** | **% Change** |
| **Net sales by Channel:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional | $38785 | $34538 | $4247 | 12.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;Specialty retail | 33411 | 38553 | (5142) | (13.3)% |
| &nbsp;&nbsp;&nbsp;&nbsp;DTC | 27173 | 23887 | 3286 | 13.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Net sales | $99369 | $96978 | $2391 | 2.5% |

---

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

Total net sales increased 2.5% for the three months ended March 31, 2026, compared to the same period in 2025. By channel, professional increased 12.3%, DTC increased 13.8% and specialty retail decreased 13.3% for the three months ended March 31, 2026, as compared to the same period in the previous year. U.S. and international net sales represented 48% and 52% of total net sales, respectively, for the three months ended March 31, 2026. U.S. and international net sales represented 51% and 49% of total net sales, respectively, for the three months ended March 31, 2025.

*Cost of Sales and Gross Profit* 

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***(in thousands)*** | **Three Months Ended**<br>**March 31,** | **Three Months Ended**<br>**March 31,** | **$ Change** | **% Change** |
|  | **2026** | **2025** | **$ Change** | **% Change** |
| Cost of sales | $27709 | $29622 | $(1913) | (6.5)% |
| Gross profit | $71660 | $67356 | $4304 | 6.4% |

---

Our cost of sales decreased primarily due to channel mix in the three months ended March 31, 2026 as compared to the same period in the previous year. In addition, the Company recorded $0.2 million in inventory write-offs during the three months ended March 31, 2026, as compared to $1.1 million recorded during the three months ended March 31, 2025.

As a result of the activity described above, our gross profit margin increased to 72.1% for the three months ended March 31, 2026 from 69.5% in the three months ended March 31, 2025.

*Operating Expenses* 

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***(in thousands)*** | **Three Months Ended**<br>**March 31,** | **Three Months Ended**<br>**March 31,** | | |
|  | **2026** | **2025** | **$ Change** | **% Change** |
| Selling, general, and administrative expenses | $65951 | $47987 | $17964 | 37.4% |
| Amortization of other intangible assets | 10820 | 10893 | (73) | (0.7)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | $76771 | $58880 | $17891 | 30.4% |

---

The increase in selling, general and administrative expenses during the three months ended March 31, 2026, compared to the same period in 2025, was primarily driven by an increase of $7.9 million in non-payroll advertising and marketing expenses, $7.4 million in Merger transaction-related costs and $3.9 million in payroll costs driven by headcount and merit increases, partially offset by a decrease of $1.6 million in other legal and professional fees.

*Interest Expense, Net*

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***(in thousands)*** | **Three Months Ended**<br>**March 31,** | **Three Months Ended**<br>**March 31,** |  |  |
|  | **2026** | **2025** | **$ Change** | **% Change** |
| Interest expense | $7132 | $13725 | $(6593) | (48.0)% |
| Interest income | (2702) | (5952) | 3250 | (54.6)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | $4430 | $7773 | $(3343) | (43.0)% |

---

Interest expense for the three months ended March 31, 2026 decreased as compared to the same period in the previous year due to our voluntary repayment of $300.0 million of outstanding principal on the 2022 Term Loan Facility on May 1, 2025, as well as lower interest rates during the three months ended March 31, 2026, as compared to the three months ended March 31, 2025.

Interest income for the three months ended March 31, 2026 decreased as compared to the same period in the previous year due to the $300.0 million principal repayment on the 2022 Term Loan Facility, which reduced available funds for investments, as well as lower interest rates during the three months ended March 31, 2026, as compared to the three months ended March 31, 2025.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

*Other Expense (Income), Net* 

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***(in thousands)*** | **Three Months Ended**<br>**March 31,** | **Three Months Ended**<br>**March 31,** |  |  |
|  | **2026** | **2025** | **$ Change** | **% Change** |
| Other expense (income), net | $142 | $(178) | $320 | (179.8)% |

---

Other expense, net was $0.1 million for the three months ended March 31, 2026, as compared to other income, net of $0.2 million for the three months ended March 31, 2025, primarily due to foreign currency transaction activity driven by the performance of the U.S. dollar.

*Income Tax (Benefit) Provision* 

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***(in thousands)*** | **Three Months Ended**<br>**March 31,** | **Three Months Ended**<br>**March 31,** |  |  |
|  | **2026** | **2025** | **$ Change** | **% Change** |
| Income tax (benefit) provision | $(4396) | $416 | $(4812) | (1156.7)% |

---

Our effective tax rate was 45.4% for the three months ended March 31, 2026, as compared to 47.2% for the three months ended March 31, 2025.

Our effective tax rate for the three months ended March 31, 2026 was higher than the statutory rate of 21% primarily due to the unfavorable impact of non-deductible stock compensation and the effect of state income taxes.

For the three months ended March 31, 2025, our effective tax rate was higher than the statutory tax rate of 21% primarily due to discrete tax expenses for a change in prior year estimates, write-off of deferred tax assets associated with net shortfalls upon vesting of restricted stock units, forfeitures of non-qualified stock options and restricted stock units and the impact of those items on the lower book income for the three months ended March 31, 2025.

**Financial Condition, Liquidity and Capital Resources**

***Overview***

Our primary recurring source of cash is the collection of proceeds from the sale of our products to our customers, including cash periodically collected in advance of delivery or performance.

Our primary use of cash is for working capital and payment of our operating costs, which consist primarily of employee-related expenses as well as general operating expenses for marketing, fulfillment costs of customer orders, overhead costs, innovation, capital expenditures and debt servicing. We also utilize cash for strategic investments and acquisitions. Fluctuations in working capital are primarily caused by customer demand for our products, timing of when a retailer rearranges or restocks our products, timing of inventory purchases, and the amount and timing of our payables and expenses, including to implement our business transformation plan. Capital expenditures typically vary and are currently limited, and future capital expenditure requirements depend on strategic initiatives selected for the fiscal year, including investments in infrastructure and expansion of our customer base.

Although international markets represented 52% of our net sales during the three months ended March 31, 2026, the majority of our bank deposits are held within the U.S.

As of March 31, 2026, we had $326.2 million of cash and cash equivalents. In addition, as of March 31, 2026, we had borrowing capacity of $150.0 million under the 2022 Revolver, providing us with a liquidity position of $476.2 million plus $48.9 million of working capital excluding cash and cash equivalents for a combined $525.1 million total liquidity position.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

***Cash Flows***

The following table summarizes our cash flows for the periods presented:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| ***(in thousands)*** | **2026** | **2025** |
| Net cash provided by (used in): |  |  |
| &nbsp;&nbsp;&nbsp;Operating activities | $7499 | $(2917) |
| &nbsp;&nbsp;&nbsp;Investing activities | (288) | (996) |
| &nbsp;&nbsp;&nbsp;Financing activities | 227 | (1161) |
| Net increase (decrease) in cash and cash equivalents | $7438 | $(5074) |

---

***Operating Activities***

Net cash provided by operating activities was $7.5 million for the three months ended March 31, 2026, primarily reflecting our net loss of $5.3 million, net of non-cash cost items and changes in operating working capital. Non-cash adjustments were primarily driven by amortization of other intangibles of $10.8 million, share-based compensation expense of $3.5 million and amortization of patent formulations of $2.4 million, partially offset by deferred taxes of $4.4 million. Changes in operating assets and liabilities decreased cash provided by operating activities by $0.8 million.

Net cash used in operating activities was $2.9 million for the three months ended March 31, 2025, primarily reflecting our net income of $0.5 million, net of non-cash cost items and changes in operating working capital. Non-cash adjustments were primarily driven by amortization of other intangibles of $10.9 million, share-based compensation expense of $2.9 million, and amortization of patent formulations of $2.4 million. Changes in operating assets and liabilities decreased cash provided by operating activities by $21.4 million.

***Investing Activities***

Net cash used in investing activities was $0.3 million for the three months ended March 31, 2026 and was related to the purchase of property and equipment and the purchase and development of software.

Net cash used in investing activities was $1.0 million for the three months ended March 31, 2025, primarily reflecting investments of $0.9 million related to the purchase and development of software.

***Financing Activities***

Net cash provided by financing activities was $0.2 million for the three months ended March 31, 2026 and consisted of proceeds from stock option exercises.

Net cash used in financing activities was $1.2 million for the three months ended March 31, 2025, consisting of $1.7 million of principal payments for the 2022 Term Loan Facility, partially offset by proceeds of $0.5 million from stock option exercises.

***Liquidity and Capital Resources Requirements***

Based on past performance and current expectations, we believe that our cash, cash equivalents and cash generated from operations will be sufficient to meet anticipated operating costs, required payments of principal and interest, working capital needs, ordinary course capital expenditures, and other commitments over both the short term (the next twelve months) and long term.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

If necessary, we may borrow funds under our 2022 Revolver to finance our liquidity requirements, subject to customary borrowing conditions. To the extent additional funds are necessary to meet our long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of additional indebtedness, equity financings or a combination of these potential sources of funds; however, such financing may not be available on favorable terms, or at all. Our ability to meet our operating, investing and financing needs depends, to a significant extent, on our future financial performance, which will be subject in part to general economic, competitive, financial, regulatory and other factors that are beyond our control, including those described in "Item 1A. - Risk Factors" in this Quarterly Report and in our 2025 Form 10-K. In addition to these general economic and industry factors, the principal factors in determining whether our cash flows will be sufficient to meet our liquidity requirements will be consumer demand for our products and our ability to continue providing innovative products to our customers and manage production and our supply chain.

***Merger Agreement***

Under the Merger Agreement, the Company has agreed to various customary covenants and agreements, including, among others, covenants to use commercially reasonable efforts to conduct its business in the ordinary course of business during the interim period between execution of the Merger Agreement and the consummation of the Merger. Outside of certain limited exceptions, the Company may not engage in or take specified actions during this period unless agreed to in writing by Parent, which include, among others:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Incurring or guaranteeing debt, except for intercompany arrangements and revolver borrowings capped at $20.0 million outstanding at any time;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Paying dividends or making distributions (other than upstream dividends among wholly owned subsidiaries);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Selling, pledging, or otherwise encumbering material assets (generally, dispositions and encumbrances of material non IP assets over $0.5 million in the aggregate are restricted, subject to ordinary-course and other exceptions), and disposing of material company-owned intellectual property other than in the ordinary course;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Making investments, loans, advances, or capital contributions to third parties above specified thresholds (generally restricted above $0.5 million in the aggregate, subject to ordinary-course employee expense advances and intercompany exceptions);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Making capital expenditures above $3.0 million per fiscal year (including authorizations and commitments);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Entering into, terminating, or materially amending material contracts in an adverse manner, or entering into new contracts that would be "material contracts" under the agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Settling litigation above specified monetary thresholds (generally restricted above $0.5 million per matter or $2.5 million aggregate, net of reserves and insurance, and also restricted if it would impose equitable relief or include an admission); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Taking other actions that could indirectly affect liquidity, including, without limitation, significant workforce actions that could trigger Worker Adjustment and Retraining Notification Act of 1988, as amended, obligations, material changes to the terms or pricing of commercial agreements outside the ordinary course of business, and amendments to certain tax elections, in each case absent any required consent or applicable-law requirement.

***2022 Credit Facility***

As of March 31, 2026, we had outstanding indebtedness under the 2022 Credit Agreement of $354.8 million. As of March 31, 2026, we had $150.0 million of available borrowing capacity under the 2022 Revolver.

The interest rate on outstanding amounts under the 2022 Term Loan Facility was 7.3% per annum as of March 31, 2026. We have not drawn on the 2022 Revolver as of March 31, 2026. The remaining balance under the 2022 Term Loan Facility is due at maturity. The maturity date of the 2022 Term Loan Facility is February 23, 2029, and the maturity date of the 2022 Revolver is February 23, 2027.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

The 2022 Credit Agreement contains a number of covenants that, among other things, restrict the Company's ability to (subject to certain exceptions) pay dividends and distributions or repurchase its capital stock, incur additional indebtedness, create liens on assets, engage in mergers or consolidations and sell or otherwise dispose of assets. The 2022 Credit Agreement also includes reporting, financial and maintenance covenants, including a springing first lien leverage ratio financial covenant that is applicable only to lenders under the 2022 Revolver. The Company was in compliance with these affirmative and negative covenants on March 31, 2026 and December 31, 2025. Substantially all the assets of the Company constitute collateral under the 2022 Credit Agreement.

In order to limit our exposure to potential increases in future interest rates related to the 2022 Term Loan Facility, on May 7, 2024, we entered into the 2024 Interest Rate Cap in connection with the 2022 Term Loan Facility, with a notional amount of $400.0 million, which amortized to $200.0 million on July 31, 2025, at a strike rate of 5.00%. The 2024 Interest Rate Cap expires on July 31, 2026. We have designated the 2024 Interest Rate Cap as a cash-flow hedge for accounting purposes.

See "Note 8 – Long-Term Debt" to the Company's Condensed Consolidated Financial Statements of this Quarterly Report for additional information.

***Tax Receivable Agreement***

In connection with the Reorganization Transactions, we entered into the Tax Receivable Agreement under which we will be required to pay to the Pre-IPO Stockholders 85% of the federal, state or local tax cash savings that we actually realize on our taxable income following the IPO, as a result of the amortization of intangible assets and capitalized transaction costs that existed as of the date of the IPO. Under the Tax Receivable Agreement, generally we will retain the benefit of the remaining 15% of the applicable tax savings.

The Tax Receivable Agreement liability is calculated based on current tax laws and the assumption that we and our subsidiaries earn sufficient taxable income to realize the full tax benefits subject to the Tax Receivable Agreement. Updates to our blended state tax rate, allocation of U.S. versus foreign sourced income and changes in U.S. tax rules may significantly impact the established liability, and changes would be recorded to Other expense (income), net in the period we made the determination.

Concurrently with the execution and delivery of the Merger Agreement, the Company entered into the Tax Receivable Agreement Waiver and Amendment, pursuant to which certain Pre-IPO Stockholders irrevocably waived their rights to receive any remaining payments under the Tax Receivable Agreement. In addition, the Tax Receivable Agreement was amended to provide for its automatic termination upon the Effective Time, subject to the payment of certain amounts to non-waiving Pre-IPO Stockholders. If the Merger Agreement is terminated in accordance with its terms, the Tax Receivable Agreement Waiver and Amendment will be null and void ab initio and all obligations under the Tax Receivable Agreement will continue in full force and effect. See further discussion in "Note 1 – Nature of Operations and Basis of Presentation – Proposed Acquisition by Henkel US Operations Corporation" to the Company's Condensed Consolidated Financial Statements of this Quarterly Report.

If the Merger Agreement is terminated and as a result the Tax Receivable Agreement Waiver and Amendment becomes null and void, we expect that future payments under the Tax Receivable Agreement relating to the Pre-IPO Tax Assets could aggregate to $165.1 million, with payments expected to continue through 2038. Payments under the Tax Receivable Agreement, which began in the year ended December 31, 2022, are not conditioned upon the Pre-IPO Stockholders' continued ownership of equity in the Company.

**Critical Accounting Estimates**

Our unaudited, interim Condensed Consolidated Financial Statements have been prepared in accordance with U.S. GAAP. The preparation of financial statements requires us to make estimates and assumptions about future events that affect amounts reported in our unaudited, interim Condensed Consolidated Financial Statements and related notes at the date of the financial statements. We evaluate our accounting estimates and judgments on an ongoing basis. We base our estimates and judgments on historical experience and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions and conditions. For additional detail regarding our critical accounting estimates, see our discussion for the year ended December 31, 2025 in the 2025 Form 10-K. There have been no material changes to these critical accounting estimates in the three months ended March 31, 2026.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK** 

There have been no material changes to our market risk exposures or management of market risk from those disclosed in Quantitative and Qualitative Disclosures About Market Risk included under Item 7A in the 2025 Form 10-K.

**ITEM 4. CONTROLS AND PROCEDURES** 

***Evaluation of Disclosure Controls and Procedures***

The Company maintains a system of disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that are designed to ensure that information required to be disclosed in its reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the U.S. Securities and Exchange Commission's ("SEC") rules and forms, and to ensure that information required to be disclosed is accumulated and communicated to management, including, as appropriate, the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

Our management has evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of March 31, 2026.

***Changes in Internal Control Over Financial Reporting***

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) or 15d-15(f) of the Exchange Act) that occurred during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

**PART II - OTHER INFORMATION** 

**ITEM 1. LEGAL PROCEEDINGS** 

We have, and may in the future, from time to time, become involved in litigation or other legal proceedings incidental to our business, including litigation related to intellectual property, regulatory matters, contract, advertising and other consumer claims. In addition, we believe that protecting our intellectual property is essential to our business and we have in the past, and may in the future, become involved in proceedings to enforce our rights. Regardless of outcome, litigation (including the litigation referenced below) can have an adverse impact on our reputation, financial condition and business, including by utilizing our resources and potentially diverting the attention of our management from the operation of our business.

For detail on certain legal proceedings, see "Note 12 – Commitments and Contingencies - Pending Legal Proceedings" to the Company's Condensed Consolidated Financial Statements of this Quarterly Report.

**ITEM 1A. RISK FACTORS** 

An investment in our common stock involves risks. Investors should carefully consider the risk factors discussed in Part I, "Item 1A. Risk Factors" in the 2025 Form 10-K, as supplemented by the risk factors set forth below, together with the other information contained in this Quarterly Report. The risks described in Part I, "Item 1A. Risk Factors" in the 2025 Form 10-K and below reflect our beliefs and opinions as to factors that could materially and adversely affect the Company and its securities in the future. If any of the following risks actually occurs, our business, prospects, operating results and financial condition could suffer materially, and the trading price of our common stock could decline. The risks and uncertainties described below and in the 2025 Form 10-K are not the only ones we face. Additional risks and uncertainties not currently known to us or those we currently view to be immaterial also may materially and adversely affect our business, prospects, operating results or financial condition. See "Special Note Regarding Forward-Looking Statements" of this Quarterly Report. The following risk factors supplement the risk factors discussed in Part I, "Item 1A. Risk Factors" in the 2025 Form 10-K.

**Risks Related to the Merger**

***Failure to complete the Merger, or delays in completing the Merger, could materially adversely affect our business, financial condition, results of operations and stock price.***

The proposed Merger is subject to various closing conditions, including, among other things, the expiration or termination of the applicable waiting period under the HSR Act and the receipt of regulatory approvals under the laws of Germany, Australia and the United Kingdom, the mailing of the information statement on Schedule 14C and the expiration of a twenty-calendar-day waiting period thereafter, the absence of any law or governmental order prohibiting the Merger, and other customary closing conditions. It is possible that a governmental authority may enjoin or otherwise prohibit the consummation of the Merger, or that certain required regulatory approvals may not be obtained on a timely basis or at all. If any condition to the closing of the Merger is not satisfied or, if permissible, waived, the Merger will not be completed. In addition, satisfying the conditions to the closing of the Merger may take longer than we expect. Furthermore, during the period between now and completion of the Merger, our business, results of operations and financial condition may be adversely impacted by, or otherwise change as a result of, a variety of factors, and such changes could affect the likelihood, timing or perceived benefits of the Merger.

The conditions to closing may not be satisfied or waived or other events may intervene to delay or result in the failure to consummate the Merger. In addition, the Merger Agreement may be terminated under certain circumstances, including if there has been a material breach by the Company of its representations, warranties or covenants or if a Company Material Adverse Effect (as defined in the Merger Agreement) has occurred since the signing of the Merger Agreement. If the Merger is not completed, our ongoing business may be adversely affected, and we will be subject to a number of risks, including the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we may be required to pay Parent a termination fee of $40,440,000 if the Merger Agreement is terminated under certain circumstances, and/or damages pursuant to the Merger Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Merger Agreement places certain restrictions on the conduct of our business, which may delay or prevent us from undertaking business opportunities that, absent the Merger Agreement, may have been pursued;

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we will still be required to pay certain significant costs relating to the Merger, such as legal, accounting, financial advisory and printing fees;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• if the Merger Agreement is terminated, the Tax Receivable Agreement Waiver and Amendment entered into in connection with the Merger may be null and void ab initio and our obligations under the Tax Receivable Agreement may continue in full force and effect; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• matters relating to the Merger (including integration planning) may require substantial commitments of time and resources by our management, which could otherwise have been devoted to other opportunities that may have been beneficial to the Company, in each case, without realizing any of the benefits of having completed the Merger, which may adversely affect our business and financial results.

The market price of our Common Stock might decline materially as a result of any such failure to complete the Merger, to the extent that the current market prices reflect a market assumption that the Merger will be completed. If that were to occur, it is uncertain when, if ever, the price of our Common Stock would return to the price levels at which shares of our Common Stock currently trade. We may also be negatively impacted if the Merger Agreement is terminated and our Board seeks but is unable to find another business combination or strategic transaction offering equivalent or more attractive benefits than the benefits expected to be provided in the Merger. Our officers or members of our Board may also be subject to litigation related to entering into or failing to consummate the Merger.

***Uncertainty about the Merger may adversely affect our business and our relationships with employees, customers, suppliers and others with whom we do business, and the Merger may disrupt our current plans and operations or divert management's attention away from ongoing business opportunities and operational matters.***

Uncertainty about the completion or effect of the Merger may affect the relationship between us and our employees, customers, manufacturers, suppliers, and other business partners which may have an adverse effect on our business, financial condition and results of operations. In addition, such uncertainty may disrupt our current plans and operations and may require a substantial commitment of time and resources by our management, which could otherwise have been devoted to other opportunities and operational matters. These uncertainties may cause customers, suppliers and others that deal with us to seek to change existing business relationships and to delay or defer decisions concerning us. Further, pursuant to the Merger Agreement, we are subject to certain restrictions during the pendency of the proposed transaction that may impact our ability to pursue certain business opportunities, strategic transactions or initiatives. Changes to existing business relationships, including termination or modification, could negatively affect our revenues, earnings and cash flow, as well as the market price of our Common Stock.

In addition, we are dependent on the experience and industry knowledge of our officers, key management personnel and other key employees to operate our business and execute our business plans. Uncertainty regarding the Merger, including the possibility of a delay in consummation or that the Merger will not be consummated, as well as uncertainty about employee roles following the Merger, may have an adverse effect on our ability to attract or retain key management personnel and other key employees. Our business could be negatively impacted if key employees depart because of issues related to the uncertainty and difficulty of integration or a desire not to remain with the business if the Merger is not consummated, and it may be difficult to attract new employees to fill such roles due to uncertainty related to the Merger. Adverse effects arising from the pendency of the Merger could be exacerbated by any delays in consummation of the Merger or termination of the Merger Agreement.

***Any legal proceedings filed against us in connection with the Merger could delay or prevent the completion of the Merger.***

Transactions such as the Merger often give rise to lawsuits by stockholders or other third parties. One of the conditions to the closing of the Merger is that the consummation of the Merger is not then prohibited or made illegal by any law, order, injunction or decree. In connection with the Merger, plaintiffs may file lawsuits against us and/or our directors and officers. Such legal proceedings could also prevent or delay the completion of the Merger and result in additional costs. In addition, if any lawsuit is successful in obtaining an injunction prohibiting us or Parent from consummating the Merger on the agreed-upon terms, the injunction may prevent the Merger from being completed within the expected timeframe, or at all. If the Merger is prevented or delayed, the lawsuits could result in substantial costs, including any costs associated with the indemnification of directors. The defense or settlement of any lawsuit or claim that remains unresolved at the time the Merger is completed may adversely affect our business, financial condition or results of operations.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

***The Merger may involve regulatory risks.***

Consummation of the Merger is conditioned upon, among other things, the expiration or termination of the waiting period under the HSR Act and the receipt of approvals, waivers or the expiration of waiting, notice, approval or review periods under the laws of Germany, Australia and the United Kingdom. These regulatory approvals may not be obtained on a timely basis or at all, and the granting of such approvals could involve the imposition of conditions that could adversely affect the Company or cause the parties to abandon the Merger. Under the Merger Agreement, the initial outside date for completion of the Merger is March 31, 2027, and will be automatically extended to September 30, 2027 if regulatory approvals remain the sole unsatisfied condition as of the initial outside date. Delays in obtaining regulatory approvals could reduce the anticipated benefits of the Merger or result in additional costs.

***The Merger Agreement contains provisions that prevent the Company from accepting an alternative acquisition.***

As a result of the execution and delivery of a written consent adopting the Merger Agreement by certain investment funds affiliated with Advent International Corporation, which held approximately 75% of the issued and outstanding shares of common stock of Olaplex Holdings as of such date, the Company is not permitted to terminate the Merger Agreement to enter into an agreement for an alternative acquisition. The Merger Agreement also contains provisions that may discourage a third party from submitting an alternative proposal to us should the Merger not be consummated, which proposal might result in greater value to our stockholders than the Merger. Specifically, we may be required to pay to Parent a termination fee in cash equal to $40,440,000 under certain circumstances involving acquisition proposals for competing transactions during a specified period following termination of the Merger Agreement. If the Merger Agreement is terminated and we determine to seek another strategic transaction, we may not be able to negotiate a transaction on terms comparable to, or better than, the terms of the proposed Merger.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS** 

None.

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES** 

None.

**ITEM 4. MINE SAFETY DISCLOSURES** 

Not applicable.

**ITEM 5. OTHER INFORMATION**

(c)During the three months ended March 31, 2026, no director or "officer" (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

**ITEM 6. EXHIBITS** 

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| <u>[2.1\*](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex21.htm)</u> | <u>[A](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex21.htm)[greement and Plan of Merger, dated as of M](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex21.htm)[arch 26, 2026, by and among Olaplex Holdings, Inc.](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex21.htm)[,](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex21.htm)[Henkel US Operations Corporation, and Margot Acquisition Merger Sub, Inc. (inco](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex21.htm)[rporated by reference to Exhibit 2.1 to the Company](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex21.htm)['](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex21.htm)[s Current Report on Form 8-K, filed on](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex21.htm)[March 26, 2026 (File No. 001-40860)).](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex21.htm)</u> |
| <u>[3.1](https://www.sec.gov/Archives/edgar/data/1868726/000186872621000010/ex31-restatedcertificateof.htm)</u> | <u>[Restated Certificate of Incorporation of Olaplex Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q, filed on November 10, 2021 (File No. 001- 40860)).](https://www.sec.gov/Archives/edgar/data/1868726/000186872621000010/ex31-restatedcertificateof.htm)</u> |
| <u>[3.2](https://www.sec.gov/Archives/edgar/data/1868726/000186872624000041/ex31amendmenttorestatedcer.htm)</u> | <u>[Certificate of Amendment to the Restated Certificate of Incorporation of Olaplex Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, filed on June 14, 2024 (File No. 001-40860)).](https://www.sec.gov/Archives/edgar/data/1868726/000186872624000041/ex31amendmenttorestatedcer.htm)</u> |
| <u>[3.3](https://www.sec.gov/Archives/edgar/data/1868726/000186872623000005/secondamendedandrestatedby.htm)</u> | <u>[Second Amended and Restated Bylaws of Olaplex Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, filed on January 20, 2023 (File No. 001-40860)).](https://www.sec.gov/Archives/edgar/data/1868726/000186872623000005/secondamendedandrestatedby.htm)</u> |
| <u>[10.1](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex101.htm)</u> | <u>[L](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex101.htm)[imited Waiver and Amendment, date](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex101.htm)[d as of March 26, 2026, by and am](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex101.htm)[ong Olaplex Holdings, Inc., the](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex101.htm)[Tax Receivable Agreement](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex101.htm)[Parties (as defined therein) and Penelope Group Holdings GP, LLC. (incorporated by reference to Exhibit 10.1 to](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex101.htm)[the Company](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex101.htm)['](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex101.htm)[s Current Report on Form 8-K, filed on March 26, 2026 (File No. 001-40860)).](https://www.sec.gov/Archives/edgar/data/1868726/000119312526126362/d119132dex101.htm)</u> |
| <u>[31.1](ex311-ceocertificationq120.htm)</u> | <u>[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex311-ceocertificationq120.htm)</u> |
| <u>[31.2](ex312-cfocertificationq120.htm)</u> | <u>[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex312-cfocertificationq120.htm)</u> |
| <u>[32.1](ex321-ceocertificationq120.htm)</u><sup>†</sup> | <u>[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex321-ceocertificationq120.htm)</u> |
| <u>[32.2](ex322-cfocertificationq120.htm)</u><sup>†</sup> | <u>[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex322-cfocertificationq120.htm)</u> |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

\*Schedules omitted pursuant to item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request, provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act, as amended, for any schedule or exhibit so furnished.

† This certification will not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.

------

<u>[**Table of Contents**](#i5e139d266af54af18d6e7944fbeebefa_10)</u>

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | OLAPLEX HOLDINGS, INC. | OLAPLEX HOLDINGS, INC. | OLAPLEX HOLDINGS, INC. |
| | By: | /s/ Amanda Baldwin | /s/ Amanda Baldwin |
| May 11, 2026 |  | Name: | Amanda Baldwin |
|  |  | Title: | Chief Executive Officer |
|  |  |  | *(Principal Executive Officer)* |
|  | By: | /s/ Catherine Dunleavy | /s/ Catherine Dunleavy |
| May 11, 2026 |  | Name: | Catherine Dunleavy |
|  |  | Title: | Chief Operating Officer and Chief Financial Officer |
|  |  |  | *(Principal Financial Officer)* |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO**

**RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Amanda Baldwin, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly Report on Form 10-Q of Olaplex Holdings, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: May 11, 2026 | By: | /s/ Amanda Baldwin |
|  |  | Amanda Baldwin |
|  |  | Chief Executive Officer |
|  |  | (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO**

**RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Catherine Dunleavy, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly Report on Form 10-Q of Olaplex Holdings, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: May 11, 2026 | By: | /s/ Catherine Dunleavy |
|  |  | Catherine Dunleavy |
|  |  | Chief Operating Officer and Chief Financial Officer |
|  |  | (Principal Financial Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO** 

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Amanda Baldwin, Chief Executive Officer of Olaplex Holdings, Inc. (the "Company"), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2026 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: May 11, 2026 | By: | /s/ Amanda Baldwin |
|  |  | Amanda Baldwin |
|  |  | Chief Executive Officer |
|  |  | (Principal Executive Officer) |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO** 

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Catherine Dunleavy, Chief Operating Officer and Chief Financial Officer of Olaplex Holdings, Inc. (the "Company"), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2026 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: May 11, 2026 | By: | /s/ Catherine Dunleavy |
|  |  | Catherine Dunleavy |
|  |  | Chief Operating Officer and Chief Financial Officer |
|  |  | (Principal Financial Officer) |

---

<br>